Nivo-Cabo Combo Joins Advanced RCC Treatment Ranks Nivo-Cabo Combo Joins Advanced RCC Treatment Ranks
The PD-1 inhibitor/TKI combination is the latest to show superior survival in comparison with sunitinib as first-line therapy for patients with metastatic renal cell carcinoma (RCC).Medscape Medical News (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - September 21, 2020 Category: Urology & Nephrology Tags: Hematology-Oncology News Source Type: news
Study Supports Changing Classification of Renal Cell Carcinoma Study Supports Changing Classification of Renal Cell Carcinoma
The definition of stage 4 renal cell carcinoma should be expanded to include lymph node-positive stage 3 disease, according to a new study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 7, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Certain pesticides linked to kidney cancer in agricultural workers
<div class="rxbodyfield">New findings from the Agricultural Health Study suggest exposure to certain pesticides may increase risk of renal cell carcinoma.</div> (read more) (Source: Environmental Factor - NIEHS Newsletter)
Source: Environmental Factor - NIEHS Newsletter - July 6, 2020 Category: Environmental Health Source Type: news
Liquid Biopsy Promising in Spotting Kidney Cancer Liquid Biopsy Promising in Spotting Kidney Cancer
An assay employing plasma and urine cell-free DNA methylomes is capable of classifying patients across all stages of renal-cell carcinoma, according to preliminary studies.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 2, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Good Survival Rates After Percutaneous Cryoablation for Early Renal Cell Carcinoma Good Survival Rates After Percutaneous Cryoablation for Early Renal Cell Carcinoma
Percutaneous cryoablation yields survival rates at least as good as those with nephrectomy in patients with stage 1 renal cell carcinoma, according to a prospective observational study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Oncotarget: Hyperprogression to immune blockade followed by a response with cabozantinib
(Impact Journals LLC) Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 10, 2020 Category: Cancer & Oncology Source Type: news
Percutaneous Cryoablation Treats Early-Stage Kidney Cancer
TUESDAY, June 9, 2020 -- Percutaneous cryoablation (PCA) for stage I renal cell carcinoma (RCC) results in good outcomes, with a 10-year disease-specific survival of 94 percent, according to a study published online June 9 in Radiology.
John... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 9, 2020 Category: Pharmaceuticals Source Type: news
Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC
Elizabeth Plimack, MD, MS, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of overall survival for axitinib and pembrolizumab over sunitinib in patients with advanced renal cell carcinoma evaluated in the updated analysis of KEYNOTE-426. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2020 Category: Cancer & Oncology Authors: Elizabeth R. Plimack, MD, MS Source Type: news
Eric Jonasch, MD, on Next Steps in MK-6482 in VHL Disease –Associated RCC
The MD Anderson Cancer Center expert discussed next steps for those with von Hippel-Lindau disease –associated renal cell carcinoma being treated with the HIF-2a Inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news
Eric Jonasch, MD, Discusses Use of MK-6482 in VHL Disease –Associated Kidney Cancer
The HIF-2a Inhibitor, MK-6482, induced clinical responses among patients with von Hippel-Lindau disease –associated renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2020 Category: Cancer & Oncology Authors: Eric Jonasch, MD Source Type: news
Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC
When compared with sorafenib, tivozanib showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news
Savolitinib Induces Encouraging Efficacy, Safety in MET-Driven Papillary Renal Cell Carcinoma
A phase III study presented the 2020 ASCO Virtual Scientific Program showed encouraging efficacy data suggesting savolitinib could be used to treat patients with MET-driven papillary renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news
Novel targeted drug induced positive response for VHL-associated kidney cancer
(University of Texas M. D. Anderson Cancer Center) In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 28, 2020 Category: Cancer & Oncology Source Type: news
Tivozanib Induces Durable Response Among Patients with Advanced Renal Cell Carcinoma
The VEGF TKI induced durable responses and favorable tolerability in patients with relapsed/refractory RCC. (Source: CancerNetwork)
Source: CancerNetwork - May 20, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
Mesothelioma Drug Combination Continues to Show Promise
Pharmaceutical giant Bristol Myers Squibb continues to tout its immunotherapy combination of Opdivo and Yervoy for first-line treatment of patients with pleural mesothelioma cancer.
Bristol Myers Squibb recently announced that overall survival “significantly improved” when the combination was measured against standard chemotherapy in a randomized, phase III clinical trial of previously untreated mesothelioma patients.
Its announcement was based on a pre-specific interim analysis conducted by the Data Monitoring Committee, a clinical study organization independent of Bristol Myers Squibb.
The study is being conducted at...
Source: Asbestos and Mesothelioma News - May 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news
